Imago BioSciences, Inc. (IMGO) Stock Analysis
DELISTED 2023
What happened to Imago BioSciences, Inc. (IMGO) stock?
Imago BioSciences, Inc. (IMGO) no longer trades on public markets. It was delisted in January 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- January 2023
- Last recorded price (historical):
- $36.01 (last quote on record before the January 2023 delisting; historical, not a current quote)
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Imago BioSciences, Inc. (IMGO). Imago BioSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for myeloproliferative neoplasms (MPNs). Their lead product candidate, bomedemstat, targets lysine-specific demethylase 1 (LSD1) and is currently in Phase II clinical trials.
Last analyzed: Mar 18, 2026Imago BioSciences, Inc. (IMGO) Healthcare & Pipeline Overview
More about this archive record
Can I still buy IMGO shares?
No. IMGO stopped trading on public markets in January 2023, so the shares are not available through a broker. Anything you see quoted for IMGO elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before IMGO stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Imago BioSciences, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.